DB18674InvestigationalProtein Based Therapies
Acimtamig is a tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct.
- Also known as
- AFM13 (ANTI CD30 X ANTI CD16) · ANTI-CD30/CD16A MONOCLONAL ANTIBODY AFM13 · Immunoglobulin, anti-(human FcγRIIIa receptor) (human heavy chain V-D-J region) fusion protein with peptide linker (GGS)3 fusion protein with immunoglobulin anti-(human CD30 antigen) (human-Mus musculus single-chain Fv fragment VL-(GGS)3-VH) fusion prot · tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct
- Code names
- AFM13
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Acimtamig, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account